Patient information centre
+ 1 646 88 33 419 (USA)
+ 44 20 38 684 002 (UK)


Post-registration experience

The publication on long-term treatment of patients suffering from rare types of cancer with the oncolytic ECHO-7 virus reveals surprisingly positive results
The medical journal APMIS, (Acta Pathologica, Microbilogica Et Immunologica Scandinavia) has published clinical cases from Latvia where, thanks to the available virotherapy, patients suffering from cancer in the last stage have considerably exceeded life expectancy that is characteristic for such diagnoses. The publication elaborates on successful oncolytic virotherapy for patients suffering from stage 4 histiocytic sarcoma, stage 3 small-cell lung cancer and stage 4 melanoma. Patients had received virotherapy over a long period and during the treatment the condition of their health and their quality of life improved considerably. Patients undergoing virotherapy treatment were diagnosed 6.6, 3.5 and 7 years ago and their condition improved and remained stable during the treatment. These cancer patients received a certain type of therapy, which was administered 1 to 2 months after diagnosis. These results are promising and allow one to believe that long-term virotherapy with this medication invented in Latvia is effective in treating sarcoma, melanoma and small-cell lung cancer. 

Immunotherapy with an adapted virus (oncolytic virotherapy) extends the survival rate of melanoma patients after the surgical removal of a tumour, retrospective study shows
The results of the retrospective study on oncolytic virotherapy efficiency have been published in the online version of the medical journal Melanoma Research dated July 15, 2015.
http://journals.lww.com/melanomaresearch/

The study reveals that the stage IB-IIC melanoma patients treated with virotherapy were 4 to 6 times more likely to survive than those who, following the current guidelines for the treatment of melanoma, received no therapy and were observed only. It has been proved that Riga Virus has an excellent safety profile, because no information has been received regarding any adverse side effects when undergoing virotherapy treatment or afterwards. Results show that the oncolytic virotherapy is a considerable gain for many patients, because it prolongs survival.
Source: Melanoma Research. 2015 July 24. Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, Venskus D, Muceniece A.

Progression-free period in stage II melanoma patients
A retrospective study, published in "Latvijas Ārsts" (Latvian Doctor), looked at the progression-free period for stage II melanoma patients. Results showed that the observed patients had a 6.7 times larger likelihood of disease recurrence than those treated with oncolytic virotherapy.
Source: Latvijas Ārsts. 2012, No.5. Doniņa et al.


← Go back



 More →




Address
Teatra 9-9, Riga,
LV-1050, Latvia

Phone
+ 44 20 38 684 002 (UK, London)
+ 1 646 88 33 419 (USA, New York)
+ 371 67 229 599 (Latvia)

E-mail
info@virotherapy.eu